The Global Plasma Derived Medicine Market, by Product Type (Albumin, Coagulation factors, Immunoglobulins, and Others), by Indication (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, and Other Orphan Diseases), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 33,450 Million in 2021 and expected to exhibit a CAGR of 6.8% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The increased adoption of inorganic strategies such as agreements and collaborations by the key market players is expected to propel the growth of the global plasma derived medicine market over the forecast period. For instance, in April 2021, TERUMO BCT, INC., a medical technology company, and CSL Plasma, one of the world's largest and most sophisticated plasma collection networks, announced a collaboration to deliver a new plasma collection platform at CSL Plasma collection centers in the U.S.
Global Plasma Derived Medicine Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.
However, plasma from COVID-19 survivors contains antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may help suppress the virus and aid the immune system's response to the infection, thus increasing the patient's chances of recovery. This has consequently prompted researchers to investigate further. In addition to lockdown, social distancing, and fear of blood virus transmission, more obstacles appeared for the blood transfusion community. The elderly, who contribute the most to donations, are among the most vulnerable to the virus, which resulted in a drop in donations from them. As a result, the global plasma derived medicine market has been negatively impacted. For instance, according to an article published by ScienceDirect in August 2020, six-month descriptive research was conducted to collect data of a blood center supporting a 1200-bed multi-specialty tertiary care academic hospital in Dehradun area of North India from October 2019 to March 2020. According to the study's findings, voluntary blood donation camps were suspended, which had a substantial impact on the blood community, resulting in a considerable drop in the number of blood donors. As a result, the blood supply was nearly depleted. During this time, all elective procedures and non-urgent clinical interventions were postponed, which resulted in a decrease in blood collection and its demand, thereby negatively impacting the global plasma derived medicine market.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Plasma Derived Medicine Market” - Forecast to 2028, Global Plasma Derived Medicine Market, by Product Type (Albumin, Coagulation factors, Immunoglobulins, and Others), by Indication (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, and Other Orphan Diseases), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/plasma-derived-medicine-market-4929
Market players are focused on the adoption of inorganic strategies such as acquisitions, which is expected to propel the global plasma derived medicine market growth over the forecast period. For instance, in September 2021, Grifols, S.A., a multinational pharmaceutical and chemical manufacturer, agreed to acquire the existing share capital of Tiancheng Pharmaceutical Holdings for US$ 1,280.59 million. Tiancheng (Germany) Pharmaceutical Holdings is the owner of 90% of Biotest ordinary shares and 1% of Biotest preferred shares. Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. With this acquisition, Biotest and Grifols will increase the availability of plasma therapies, ensuring greater patient access to plasma medicines across the world.
Key Takeaways of the Global Plasma Derived Medicine Market:
- The global plasma derived medicine market is expected to exhibit a CAGR of 6.8% during the forecast period, due to the increasing adoption of inorganic strategies by the key market players, such as agreements. For instance, in November 2020, Grifols, S.A., a multinational pharmaceutical and chemical manufacturer, and the National Service Projects Organization (NSPO), an organization that manufactures military and civilian products and provides contracting services, entered into a strategic agreement to develop the local plasma-derived therapies market by opening 20 plasma centers and constructing production facilities in Egypt, including a plasma fractionation plant and protein purification plants.
- Among product types, the immunoglobulins segment is estimated to hold a dominant position in the global plasma derived medicine market over the forecast period, owing to its increased use in primary immunodeficiency and neurological applications and approvals from regulatory bodies for immunoglobulin plasma-derived medicines. For instance, in July 2019, SK Plasma, a company specialized in plasma-derived medicine, announced that it had received approval from the Ministry of Food and Drug Safety for its immunoglobulin product 10g Liv-Gamma SN Inj, a plasma-derived product that has various indications such as Guillain-Barre Syndrome (GBS), gammaglobulinemia, Kawasaki disease, etc.
- On the basis of region, North America is expected to account for the largest market share in the global plasma derived medicine market over the forecast period, owing to the increasing research activities and adoption of inorganic strategies such as acquisitions by the key players in the region. For instance, in October 2021, Kedrion, an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products, completed the acquisition of the Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., a biotechnology company, in North America. This strategic acquisition will help bring therapies to patients who suffer from rare diseases such as plasminogen deficiency.
- Major players operating in the global plasma derived medicine market include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG
